Varenicline improves motor and cognitive symptoms in early Huntington's disease
The aim of this study was to describe the effects of varenicline, a smoking cessation aid that acts as a nicotinic agonist, on cognitive function in patients with early clinical Huntington's disease (HD) who were current smokers. Three gene-positive patients transitioning to symptomatic HD were...
Gespeichert in:
| Veröffentlicht in: | Neuropsychiatric disease and treatment 2016-01, Vol.12, p.2381-2386 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2386 |
|---|---|
| container_issue | |
| container_start_page | 2381 |
| container_title | Neuropsychiatric disease and treatment |
| container_volume | 12 |
| creator | McGregor, Ailsa L Dysart, Jo Tingle, Malcolm D Russell, Bruce R Kydd, Rob R Finucane, Gregory |
| description | The aim of this study was to describe the effects of varenicline, a smoking cessation aid that acts as a nicotinic agonist, on cognitive function in patients with early clinical Huntington's disease (HD) who were current smokers. Three gene-positive patients transitioning to symptomatic HD were evaluated using the Unified Huntington's Disease Rating Scale part I and III (motor and behavioral subscales) at baseline and after 4 weeks of treatment. Cognitive function was assessed using a touch screen computer-based neurocognitive test battery (IntegNeuro
). Varenicline (1 mg twice daily) significantly improved performance in executive function and emotional recognition tasks. Our case reports describe no clinically significant adverse effects and suggest that varenicline improves aspects of cognitive function in patients with early HD. A randomized controlled study is now underway. |
| doi_str_mv | 10.2147/NDT.S111083 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5034909</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A506651455</galeid><sourcerecordid>A506651455</sourcerecordid><originalsourceid>FETCH-LOGICAL-c507t-5fc436ccf8898a374aa372d6bab3e0e8ca6869654b9f2c6819de69fc80696b793</originalsourceid><addsrcrecordid>eNptkt9rFDEQxxdRbK0--S4BQQXZMz82P_ZFKG21QrEPVl9DNjt7l7KbnEn24P57c_asPZHAZJj5zDdk-FbVS4IXlDTyw9fzm8U3QghW7FF1TIhUNcWUPP6di1owqo6qZyndYsxkq9TT6ohK0XLGxHF1_cNE8M6OzgNy0zqGDSQ0hRwiMr5HNiy9y24DKG2ndQ5TQs4jMHHcosvZZ-eXOfi3CfUugUnwvHoymDHBi_19Un3_dHFzdllfXX_-cnZ6VVuOZa75YBsmrB2UapVhsjEl0F50pmOAQVkjlGgFb7p2oFYo0vYg2sEqXKqdbNlJ9fFOdz13E_QWfI5m1OvoJhO3OhinDzverfQybDTHrGnxTuDdXiCGnzOkrCeXLIyj8RDmpIlinEnRqB36-h_0NszRl-9pShssuRKK_qWWZgTt_BDKu3Ynqk85FoKThvNCLf5DldPD5GzwMLhSPxh482BgBWbMqxTGObvg0yH4_g60MaQUYbhfBsF6ZxRdjKL3Rin0q4f7u2f_OIP9Aq1xt4I</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2240758682</pqid></control><display><type>article</type><title>Varenicline improves motor and cognitive symptoms in early Huntington's disease</title><source>Taylor & Francis Open Access</source><source>DOVE Medical Press Journals</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>McGregor, Ailsa L ; Dysart, Jo ; Tingle, Malcolm D ; Russell, Bruce R ; Kydd, Rob R ; Finucane, Gregory</creator><creatorcontrib>McGregor, Ailsa L ; Dysart, Jo ; Tingle, Malcolm D ; Russell, Bruce R ; Kydd, Rob R ; Finucane, Gregory</creatorcontrib><description>The aim of this study was to describe the effects of varenicline, a smoking cessation aid that acts as a nicotinic agonist, on cognitive function in patients with early clinical Huntington's disease (HD) who were current smokers. Three gene-positive patients transitioning to symptomatic HD were evaluated using the Unified Huntington's Disease Rating Scale part I and III (motor and behavioral subscales) at baseline and after 4 weeks of treatment. Cognitive function was assessed using a touch screen computer-based neurocognitive test battery (IntegNeuro
). Varenicline (1 mg twice daily) significantly improved performance in executive function and emotional recognition tasks. Our case reports describe no clinically significant adverse effects and suggest that varenicline improves aspects of cognitive function in patients with early HD. A randomized controlled study is now underway.</description><identifier>ISSN: 1176-6328</identifier><identifier>ISSN: 1178-2021</identifier><identifier>EISSN: 1178-2021</identifier><identifier>DOI: 10.2147/NDT.S111083</identifier><identifier>PMID: 27695336</identifier><language>eng</language><publisher>New Zealand: Dove Medical Press Limited</publisher><subject>Age ; Anxiety ; Apathy ; Brain research ; Case Series ; Clinical significance ; Cognition & reasoning ; Cognitive ability ; Education ; Emotions ; Executive function ; High definition television ; Huntingtons disease ; Nicotine ; Patients ; Smoking cessation ; Smoking cessation products ; Studies</subject><ispartof>Neuropsychiatric disease and treatment, 2016-01, Vol.12, p.2381-2386</ispartof><rights>COPYRIGHT 2016 Dove Medical Press Limited</rights><rights>2016. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2016 McGregor et al. This work is published and licensed by Dove Medical Press Limited 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c507t-5fc436ccf8898a374aa372d6bab3e0e8ca6869654b9f2c6819de69fc80696b793</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034909/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034909/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,3860,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27695336$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>McGregor, Ailsa L</creatorcontrib><creatorcontrib>Dysart, Jo</creatorcontrib><creatorcontrib>Tingle, Malcolm D</creatorcontrib><creatorcontrib>Russell, Bruce R</creatorcontrib><creatorcontrib>Kydd, Rob R</creatorcontrib><creatorcontrib>Finucane, Gregory</creatorcontrib><title>Varenicline improves motor and cognitive symptoms in early Huntington's disease</title><title>Neuropsychiatric disease and treatment</title><addtitle>Neuropsychiatr Dis Treat</addtitle><description>The aim of this study was to describe the effects of varenicline, a smoking cessation aid that acts as a nicotinic agonist, on cognitive function in patients with early clinical Huntington's disease (HD) who were current smokers. Three gene-positive patients transitioning to symptomatic HD were evaluated using the Unified Huntington's Disease Rating Scale part I and III (motor and behavioral subscales) at baseline and after 4 weeks of treatment. Cognitive function was assessed using a touch screen computer-based neurocognitive test battery (IntegNeuro
). Varenicline (1 mg twice daily) significantly improved performance in executive function and emotional recognition tasks. Our case reports describe no clinically significant adverse effects and suggest that varenicline improves aspects of cognitive function in patients with early HD. A randomized controlled study is now underway.</description><subject>Age</subject><subject>Anxiety</subject><subject>Apathy</subject><subject>Brain research</subject><subject>Case Series</subject><subject>Clinical significance</subject><subject>Cognition & reasoning</subject><subject>Cognitive ability</subject><subject>Education</subject><subject>Emotions</subject><subject>Executive function</subject><subject>High definition television</subject><subject>Huntingtons disease</subject><subject>Nicotine</subject><subject>Patients</subject><subject>Smoking cessation</subject><subject>Smoking cessation products</subject><subject>Studies</subject><issn>1176-6328</issn><issn>1178-2021</issn><issn>1178-2021</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkt9rFDEQxxdRbK0--S4BQQXZMz82P_ZFKG21QrEPVl9DNjt7l7KbnEn24P57c_asPZHAZJj5zDdk-FbVS4IXlDTyw9fzm8U3QghW7FF1TIhUNcWUPP6di1owqo6qZyndYsxkq9TT6ohK0XLGxHF1_cNE8M6OzgNy0zqGDSQ0hRwiMr5HNiy9y24DKG2ndQ5TQs4jMHHcosvZZ-eXOfi3CfUugUnwvHoymDHBi_19Un3_dHFzdllfXX_-cnZ6VVuOZa75YBsmrB2UapVhsjEl0F50pmOAQVkjlGgFb7p2oFYo0vYg2sEqXKqdbNlJ9fFOdz13E_QWfI5m1OvoJhO3OhinDzverfQybDTHrGnxTuDdXiCGnzOkrCeXLIyj8RDmpIlinEnRqB36-h_0NszRl-9pShssuRKK_qWWZgTt_BDKu3Ynqk85FoKThvNCLf5DldPD5GzwMLhSPxh482BgBWbMqxTGObvg0yH4_g60MaQUYbhfBsF6ZxRdjKL3Rin0q4f7u2f_OIP9Aq1xt4I</recordid><startdate>20160101</startdate><enddate>20160101</enddate><creator>McGregor, Ailsa L</creator><creator>Dysart, Jo</creator><creator>Tingle, Malcolm D</creator><creator>Russell, Bruce R</creator><creator>Kydd, Rob R</creator><creator>Finucane, Gregory</creator><general>Dove Medical Press Limited</general><general>Taylor & Francis Ltd</general><general>Dove Medical Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88G</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M2M</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160101</creationdate><title>Varenicline improves motor and cognitive symptoms in early Huntington's disease</title><author>McGregor, Ailsa L ; Dysart, Jo ; Tingle, Malcolm D ; Russell, Bruce R ; Kydd, Rob R ; Finucane, Gregory</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c507t-5fc436ccf8898a374aa372d6bab3e0e8ca6869654b9f2c6819de69fc80696b793</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Age</topic><topic>Anxiety</topic><topic>Apathy</topic><topic>Brain research</topic><topic>Case Series</topic><topic>Clinical significance</topic><topic>Cognition & reasoning</topic><topic>Cognitive ability</topic><topic>Education</topic><topic>Emotions</topic><topic>Executive function</topic><topic>High definition television</topic><topic>Huntingtons disease</topic><topic>Nicotine</topic><topic>Patients</topic><topic>Smoking cessation</topic><topic>Smoking cessation products</topic><topic>Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>McGregor, Ailsa L</creatorcontrib><creatorcontrib>Dysart, Jo</creatorcontrib><creatorcontrib>Tingle, Malcolm D</creatorcontrib><creatorcontrib>Russell, Bruce R</creatorcontrib><creatorcontrib>Kydd, Rob R</creatorcontrib><creatorcontrib>Finucane, Gregory</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neuropsychiatric disease and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>McGregor, Ailsa L</au><au>Dysart, Jo</au><au>Tingle, Malcolm D</au><au>Russell, Bruce R</au><au>Kydd, Rob R</au><au>Finucane, Gregory</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Varenicline improves motor and cognitive symptoms in early Huntington's disease</atitle><jtitle>Neuropsychiatric disease and treatment</jtitle><addtitle>Neuropsychiatr Dis Treat</addtitle><date>2016-01-01</date><risdate>2016</risdate><volume>12</volume><spage>2381</spage><epage>2386</epage><pages>2381-2386</pages><issn>1176-6328</issn><issn>1178-2021</issn><eissn>1178-2021</eissn><abstract>The aim of this study was to describe the effects of varenicline, a smoking cessation aid that acts as a nicotinic agonist, on cognitive function in patients with early clinical Huntington's disease (HD) who were current smokers. Three gene-positive patients transitioning to symptomatic HD were evaluated using the Unified Huntington's Disease Rating Scale part I and III (motor and behavioral subscales) at baseline and after 4 weeks of treatment. Cognitive function was assessed using a touch screen computer-based neurocognitive test battery (IntegNeuro
). Varenicline (1 mg twice daily) significantly improved performance in executive function and emotional recognition tasks. Our case reports describe no clinically significant adverse effects and suggest that varenicline improves aspects of cognitive function in patients with early HD. A randomized controlled study is now underway.</abstract><cop>New Zealand</cop><pub>Dove Medical Press Limited</pub><pmid>27695336</pmid><doi>10.2147/NDT.S111083</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1176-6328 |
| ispartof | Neuropsychiatric disease and treatment, 2016-01, Vol.12, p.2381-2386 |
| issn | 1176-6328 1178-2021 1178-2021 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5034909 |
| source | Taylor & Francis Open Access; DOVE Medical Press Journals; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Age Anxiety Apathy Brain research Case Series Clinical significance Cognition & reasoning Cognitive ability Education Emotions Executive function High definition television Huntingtons disease Nicotine Patients Smoking cessation Smoking cessation products Studies |
| title | Varenicline improves motor and cognitive symptoms in early Huntington's disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T03%3A17%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Varenicline%20improves%20motor%20and%20cognitive%20symptoms%20in%20early%20Huntington's%20disease&rft.jtitle=Neuropsychiatric%20disease%20and%20treatment&rft.au=McGregor,%20Ailsa%20L&rft.date=2016-01-01&rft.volume=12&rft.spage=2381&rft.epage=2386&rft.pages=2381-2386&rft.issn=1176-6328&rft.eissn=1178-2021&rft_id=info:doi/10.2147/NDT.S111083&rft_dat=%3Cgale_pubme%3EA506651455%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2240758682&rft_id=info:pmid/27695336&rft_galeid=A506651455&rfr_iscdi=true |